Diseases (25)
Screening/Initial Testing (1)

Note: May be considered in patients with suspected or known familial cancer syndrome(s). Typically testing is every 6 months beginning at age 30.
Diagnostic Testing (11)

Note: CA-125 may be increased in patients with endometriosis but it is not specific (J Obstet Gynaecol Can 2024 May;46(5):102450).

Note: If occult malignancy is suspected.

Note: Might be elevated in hypothyroidsm. BMJ 2002 Oct 26;325(7370):946
Other Supportive/Alternative Tests (10)

Note: Elevated CA-125 is seen in patients with pelvic actinomycosis.

Note: Aid in diagnosis and management of ovarian cancer.

Note: Not specific, but supportive of diagnosis and treatment.

Note: Not specific, but might be supportive for diagnosis and treatment.

Note: Not specific for testicular cancer, but might be supportive for diagnosis and treatment.

Note: Not specific for breast cancer, but might be supportive for diagnosis and treatment.

Note: Not specific for kidney cancer, but might be supportive for diagnosis and treatment.

Note: Not specific, but supportive for diagnosis and treatment.

Note: Not specific for mesothelioma, but can be supportive.

Note: Not specific, but supportive.

Overview

CA 125 is a cell surface protein often found on ovarian cancer cells and in some normal tissues. It is one of the protein antigens that has been associated with the presence of various cancers, but is most often positive in ovarian cancer. CA 125 concentrations may also be elevated in other types of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease. CA 125 is a useful tumor marker for evaluating therapy and monitoring disease status in ovarian cancer patients. As the levels decrease it is an indication that the therapy or treatment is working. Post-operatively, the CA 125 concentration correlates with tumor bulk and is a prognostic indicator of clinical outcome. It has been reported that patients with levels exceeding 35 U/mL have the highest risk for clinical recurrence. CA 125 is not useful as a screening mechanism because it is elevated in many non-cancerous conditions, although women that are at higher risk due to family history or other reasons are usually tested regularly as a precautionary method.

Measured serially, serum CA 125 concentration typically corresponds with disease progression or regression. The rate of change in CA 125 is also highly prognostic. A rapid decrease in the level of CA 125 indicates a positive response to treatment. Elevated levels of CA 125 after the third course of primary chemotherapy are typically predictive of poor outcomes.

Clinical Utility

  • Monitoring and management of ovarian cancer of epithelial type, including monitoring for disease after initial treatment.
  • Management of ovarian epithelial cancer patients with metastatic disease by monitoring the progression or regression of disease response to treatment

Interpretation

Increased in:

  • Ovarian cancer of epithelial types
  • Pelvic inflammatory disease
  • Some other cancers
  • Cancer of endometrium
  • Cancer of fallopian tube
  • Some physiological conditions such as pregnancy, menstruation
  • Endometriosis
  • Ovarian cysts

Note: Normal levels do not exclude recurrent malignancy.

Reference Ranges

 <30 U/mL

 

 

Methodology
Enzyme Immunoassay, ELISA

Specimen Collection

Serum (SST).

Stability

  • Ambient: 24 hours
  • Refrigerated: 7 days
  • Frozen: 60 days
  • Separate sample within 1 hour of collection and keep refrigerated or frozen.

Additional Testing

Carcinoembryonic antigen (CEA), CA 15-3, CA 19-9, Follicle Stimulating Hormone, Luteinizing Hormone, HCG, Progesterone, HE4.

CPT
86304$20.81

ICD10
  • AK - Alaska
  • AL - Alabama
  • AR - Arkansas
  • AS - American Samoa
  • AZ - Arizona
  • CA - California - Entire State
  • CO - Colorado
  • CT - Connecticut
  • DC - District of Columbia
  • DE - Delaware
  • FL - Florida
  • GA - Georgia
  • GU - Guam
  • HI - Hawaii
  • IA - Iowa
  • ID - Idaho
  • IL - Illinois
  • IN - Indiana
  • KS - Kansas
  • KY - Kentucky
  • LA - Louisiana
  • MA - Massachusetts
  • MD - Maryland
  • ME - Maine
  • MI - Michigan
  • MN - Minnesota
  • MO - Missouri - Entire State
  • MS - Mississippi
  • MT - Montana
  • NC - North Carolina
  • ND - North Dakota
  • NE - Nebraska
  • NH - New Hampshire
  • NJ - New Jersey
  • NM - New Mexico
  • NV - Nevada
  • NY - New York - Entire State
  • OH - Ohio
  • OK - Oklahoma
  • OR - Oregon
  • PA - Pennsylvania
  • PR - Puerto Rico
  • RI - Rhode Island
  • SC - South Carolina
  • SD - South Dakota
  • TN - Tennessee
  • TX - Texas
  • UT - Utah
  • VA - Virginia
  • VI - Virgin Islands
  • VT - Vermont
  • WA - Washington
  • WI - Wisconsin
  • WV - West Virginia
  • WY - Wyoming
  • CNMI - Northern Mariana Islands
  • EM - Missouri - Northeastern & Southern
  • WM - Missouri - Northwestern
  • DN - New York - Downstate
  • QN - New York - Queens
  • UN - New York - Upstate
  • NF - California - Northern
  • SF - California - Southern
Showing results for all states.
Filter:
ICD10 CODE AND DESCRIPTIONLCD CODENCD CODE
A41 - Other sepsis——
A41.89 - Other specified sepsis——
A42 - Actinomycosis——
A42.0 - Pulmonary actinomycosis——
A42.1 - Abdominal actinomycosis——
A42.2 - Cervicofacial actinomycosis——
A42.7 - Actinomycotic sepsis——
A42.8 - Other forms of actinomycosis——
A42.81 - Actinomycotic meningitis——
A42.82 - Actinomycotic encephalitis——
A42.89 - Other forms of actinomycosis——
A42.9 - Actinomycosis, unspecified——
B18.0 - Chronic viral hepatitis B with delta-agent——
B18.1 - Chronic viral hepatitis B without delta-agent——
B18.2 - Chronic viral hepatitis C——
B18.8 - Other chronic viral hepatitis——
B20 - Human immunodeficiency virus [HIV] disease——
B44 - Aspergillosis——
B44.9 - Aspergillosis, unspecified——
B97.7 - Papillomavirus as the cause of diseases classified elsewhere——
C22 - Malignant neoplasm of liver and intrahepatic bile ducts——
C22.0 - Liver cell carcinoma——
C22.1 - Intrahepatic bile duct carcinoma——
C22.7 - Other specified carcinomas of liver——
C22.8 - Malignant neoplasm of liver, primary, unspecified as to type——
C22.9 - Malignant neoplasm of liver, not specified as primary or secondary——
C25 - Malignant neoplasm of pancreas——
C25.0 - Malignant neoplasm of head of pancreas——
C25.1 - Malignant neoplasm of body of pancreas——
C25.2 - Malignant neoplasm of tail of pancreas——
C25.4 - Malignant neoplasm of endocrine pancreas——
C25.7 - Malignant neoplasm of other parts of pancreas——
C25.8 - Malignant neoplasm of overlapping sites of pancreas——
C25.9 - Malignant neoplasm of pancreas, unspecified——
C38 - Malignant neoplasm of heart, mediastinum and pleura——
C38.0 - Malignant neoplasm of heart——
C38.1 - Malignant neoplasm of anterior mediastinum——
C38.2 - Malignant neoplasm of posterior mediastinum——
C38.3 - Malignant neoplasm of mediastinum, part unspecified——
C38.4 - Malignant neoplasm of pleura——
C38.8 - Malignant neoplasm of overlapping sites of heart, mediastinum and pleura——
C39 - Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs——
C39.0 - Malignant neoplasm of upper respiratory tract, part unspecified——
C43.52 - Malignant melanoma of skin of breast——
C44 - Other and unspecified malignant neoplasm of skin——
C44.501 - Unspecified malignant neoplasm of skin of breast——
C45 - Mesothelioma——
C45.0 - Mesothelioma of pleura——
C45.1 - Mesothelioma of peritoneum——
C45.2 - Mesothelioma of pericardium——

Additional ICD10
  • AK - Alaska
  • AL - Alabama
  • AR - Arkansas
  • AS - American Samoa
  • AZ - Arizona
  • CA - California - Entire State
  • CO - Colorado
  • CT - Connecticut
  • DC - District of Columbia
  • DE - Delaware
  • FL - Florida
  • GA - Georgia
  • GU - Guam
  • HI - Hawaii
  • IA - Iowa
  • ID - Idaho
  • IL - Illinois
  • IN - Indiana
  • KS - Kansas
  • KY - Kentucky
  • LA - Louisiana
  • MA - Massachusetts
  • MD - Maryland
  • ME - Maine
  • MI - Michigan
  • MN - Minnesota
  • MO - Missouri - Entire State
  • MS - Mississippi
  • MT - Montana
  • NC - North Carolina
  • ND - North Dakota
  • NE - Nebraska
  • NH - New Hampshire
  • NJ - New Jersey
  • NM - New Mexico
  • NV - Nevada
  • NY - New York - Entire State
  • OH - Ohio
  • OK - Oklahoma
  • OR - Oregon
  • PA - Pennsylvania
  • PR - Puerto Rico
  • RI - Rhode Island
  • SC - South Carolina
  • SD - South Dakota
  • TN - Tennessee
  • TX - Texas
  • UT - Utah
  • VA - Virginia
  • VI - Virgin Islands
  • VT - Vermont
  • WA - Washington
  • WI - Wisconsin
  • WV - West Virginia
  • WY - Wyoming
  • CNMI - Northern Mariana Islands
  • EM - Missouri - Northeastern & Southern
  • WM - Missouri - Northwestern
  • DN - New York - Downstate
  • QN - New York - Queens
  • UN - New York - Upstate
  • NF - California - Northern
  • SF - California - Southern
Showing results for all states.
Filter:
ICD10 CODE AND DESCRIPTIONLCD CODENCD CODE
A41.0 - Sepsis due to Staphylococcus aureus——
A41.01 - Sepsis due to Methicillin susceptible Staphylococcus aureus——
A41.02 - Sepsis due to Methicillin resistant Staphylococcus aureus——
A41.1 - Sepsis due to other specified staphylococcus——
A41.2 - Sepsis due to unspecified staphylococcus——
A41.3 - Sepsis due to Hemophilus influenzae——
A41.4 - Sepsis due to anaerobes——
A41.5 - Sepsis due to other Gram-negative organisms——
A41.50 - Gram-negative sepsis, unspecified——
A41.51 - Sepsis due to Escherichia coli [E. coli]——
A41.52 - Sepsis due to Pseudomonas——
A41.53 - Sepsis due to Serratia——
A41.54 - Sepsis due to Acinetobacter baumannii——
A41.59 - Other Gram-negative sepsis——
A41.8 - Other specified sepsis——
A41.81 - Sepsis due to Enterococcus——
A41.89 - Other specified sepsis——
A41.9 - Sepsis, unspecified organism——
A42.0 - Pulmonary actinomycosis——
A42.1 - Abdominal actinomycosis——
A42.2 - Cervicofacial actinomycosis——
A42.7 - Actinomycotic sepsis——
A42.8 - Other forms of actinomycosis——
A42.81 - Actinomycotic meningitis——
A42.82 - Actinomycotic encephalitis——
A42.89 - Other forms of actinomycosis——
A42.9 - Actinomycosis, unspecified——
B44.0 - Invasive pulmonary aspergillosis——
B44.1 - Other pulmonary aspergillosis——
B44.2 - Tonsillar aspergillosis——
B44.7 - Disseminated aspergillosis——
B44.8 - Other forms of aspergillosis——
B44.81 - Allergic bronchopulmonary aspergillosis——
B44.89 - Other forms of aspergillosis——
B44.9 - Aspergillosis, unspecified——
C22.0 - Liver cell carcinoma——
C22.1 - Intrahepatic bile duct carcinoma——
C22.2 - Hepatoblastoma——
C22.3 - Angiosarcoma of liver——
C22.4 - Other sarcomas of liver——
C22.7 - Other specified carcinomas of liver——
C22.8 - Malignant neoplasm of liver, primary, unspecified as to type——
C22.9 - Malignant neoplasm of liver, not specified as primary or secondary——
C25.0 - Malignant neoplasm of head of pancreas——
C25.1 - Malignant neoplasm of body of pancreas——
C25.2 - Malignant neoplasm of tail of pancreas——
C25.3 - Malignant neoplasm of pancreatic duct——
C25.4 - Malignant neoplasm of endocrine pancreas——
C25.7 - Malignant neoplasm of other parts of pancreas——
C25.8 - Malignant neoplasm of overlapping sites of pancreas——

References